Sanofi US Issues Auvi-Q Recall

Sanofi US has issued a voluntary nationwide recall of Auvi-Q® (epinephrine injection, USP) due to potential inaccurate dosage delivery. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). The concern is that if a patient was experiencing anaphylaxis and ended up not receiving the intended dose, there could be significant implications due to the potentially life-threatening nature of anaphylaxis.

The recall covers all Auvi-Q units currently on the market in both the 0.15 mg and 0.3 mg strengths. This includes lot numbers 2081278 through 3037230, which expire October 2015 through December 2016.

AAAAI members should be aware of this recall because the manufacturer is urging patients to promptly contact their healthcare provider to arrange for a prescription for an alternate epinephrine autoinjector. The manufacturer is also advising patients to contact their healthcare provider if they experience any issues that may be related to using the product.

If your patients have questions related to the recall, they can visit Auvi‑Q.com and call 1‑866‑726‑6340 or 1-877-319-8963 Monday through Friday (8 am to 8 pm ET) for assistance on how to return their devices.

AAAAI members are also urged to visit Auvi-Q.com for more detailed information, as well as a helpful set of questions and answers.